Hologic agreed to be acquired by funds led by Blackstone and TPG in a transaction valued up to $18.3 billion, including contingent value rights tied to breast-health revenue targets. The board unanimously approved the cash offer, which includes a 45-day go-shop period and contemplates delisting Hologic upon close. Buyout investors signalled commitments from sovereign and institutional partners and arranged financing from multiple banks. The deal concentrates private capital into a high-margin med‑tech franchise and highlights investor interest in diagnostic and women’s‑health assets amid public-market pressure. Hologic management emphasised the transaction will support product innovation and global expansion while offering immediate value to shareholders.